In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20–25%. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40% and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50%) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.

Keywords:
Ifosfamide, Non-small cell lung cancer, Advanced stage
1.
Non-Small Cell Lung Cancer Cooperative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patient data from 52 randomised clinical trials. BMJ 1995;311:899–909.
2.
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessel E, Connolly CK, Tobias J, Souhami RL: Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999;17:3188–3194.
3.
Vokes EE, Vijayakumar S, Bitran JD: Role of systemic therapy in advanced non-small cell lung cancer. Am J Med 1990;89:777–786.
4.
Splinter TAW: Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol 1990;26:1093–1099.
5.
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1994;12:1821–1826.
6.
Fossella FV, Lee JS, Murphy WK: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994;12:1238–1244.
7.
Hainsworth JD, Thomson DS, Greco A: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609–1614.
8.
Depierre A, Lemarié E, Dabouis G: A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115–119.
9.
Bonomi P, Kim K, Chang A, Johnson D: Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin-G-CSF versus taxol-cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996;15:382a.
10.
Le Chevalier T, Brisgand D, Douillard JY: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European trial including 612 patients. J Clin Oncol 1994;12:360–367.
11.
Sandler AB, Nemungitis J, Deham C: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122–130.
12.
Berger DP, Fiebig HH, Winterhalter BR, Wallbrecher E, Henss H: Preclinical phase II study of ifosfamide in human tumor xenografts in vivo. Cancer Chemother Pharmacol 1990;26:7–11.
13.
Johnson DH: Overview of ifosfamide in small cell and non-small cell lung cancer. Semin Oncol 1990;6:87–98.
14.
Eberhardt W, Niederle N: Ifosfamide in non-small cell lung cancer: A review. Semin Oncol 1992;19:40–48.
15.
Goldin A: Ifosfamide in experimental systems. Semin Oncol 1982;9:14–23.
16.
Crinò L, Clerici M, Figoli F: Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimens: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995;6:347–353.
17.
Sculier JP, Paesmans M, Thiriaux J: Phase III randomised trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small cell lung cancer. J Clin Oncol 1998;16:1388–1396.
18.
Rosell R, Moreno I, Maestre J: Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced non-small cell lung cancer: A meta-analytic review. J Surg Oncol 1990;45:124–130.
19.
Vergnenegre A, Thomas P, Robiner G, Pibarot M, Paillotin D, Vernejoux JM, Thiberville L, Lena H, Kleisbauer JP, Gimonet JF: Ifosfamide à forte dose chez des patients porteurs de cancers bronchiques non à petites cellules de stade IV: Essai de phase II du Groupe français de pneumo-cancérologie (GFPC). Bull Cancer 1999;86:1017–1021.
20.
Girón CG, Ordoñez A, Jalon JI, Barón MG: Combined chemotherapy with ifosfamide, mitomycin and cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 1987;71:851–853.
21.
Cullen MH, Joshi R, Chetiyawardanaa AD, Woodroffe CM: Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: Treatment good enough to compare. Br J Cancer 1988;58:359–361.
22.
Crinò L, Scagliotti G, Ricci S, et al: Gemcitabine-cisplatin versus mitomycin C-ifosfamide-cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522–3530.
23.
Masters GA, Hoffman PC, Hsieh A, Drinkard LC, Mick R, Samuels BL, Guaspari A, Golomb HM, Vokes EE: Phase I study of vinorelbine and ifosfamide in advanced non-small cell lung cancer. J Clin Oncol 1997;15:884–892.
24.
Perry MC, Ihde DC, Herndon II JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR: Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000;28:63–68.
25.
Hoffman PC, Masters GA, Drinkard LC: Ifosfamide plus paclitaxel in advanced non-small cell lung cancer: A phase I study. Ann Oncol 1996;7:314–316.
26.
Marx G, Lewis C, Hall K, Levi J, Ackland S: Phase I study of docetaxel plus ifosfamide in patients with advanced cancer. Br J Cancer 2002;87:846–849.
27.
Baldini E, Tibaldi C, Chella A, Angeletti CA, Silvano G, Andrei A, Algeri R, Conte PF: Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small cell lung cancer. Ann Oncol 1996;7:747–749.
28.
Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bander M, Pannucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R: Cisplatin-vindesine-mitomycin (MVP) vs. cisplatin-ifosfamide-vinorelbine (PIN) vs. carboplatin-vinorelbine (CaN) in patients with advanced non-small cell lung cancer: A FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). Br J Cancer 1998;77:2367–2370.
29.
Souquet PJ, Foumel P, Bohas CM, Court Fortune I, Chatte G: Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small cell lung cancer. Semin Oncol 1996;2(suppl 5):8–10.
30.
Tan EH, Ang PT, Wee J, Fong KW, Leong SS, Khoo KS: Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer. Acta Oncol 1999;38:619–622.
31.
Rey F, Astoul P, Marqueste L, Petite JM, Boutin C, Viallat JR: Cisplatin, ifosfamide and vinorelbine combination chemotherapy in stage III–IV non-small cell lung cancer. Am J Clin Oncol 1998;21:518–522.
32.
Tognoni A, Cadenotti L, Pensa F, Vaira F, Vigani A, Bancalari L, Cordani S, Maggiani R, Canessa PA, Pronzato P: A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granlocyte-colony stimulating factor in advanced non-small cell lung cancer. J Chemother 1999;11:306–309.
33.
Barone C, Corsi DC, Pozzo C, Cassano A, Alvaro G, Colloca G, Landriscina M, Astone A: Vinorelbine and alternating cisplatin and ifosfamide in the treatment of non-small cell lung cancer. Oncology 2000;58:25–30.
34.
Bae Ahn J, Ko WK, Lee JG, Shim KY, Jeung HC, Park JO, Yoo NC, Kim BS, Kim SK, Kim SK, Kim JH: Effect of vinorelbine, ifosfamide and cisplatin combination chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2000;23:622–628.
35.
Baldini E, Silvano G, Tibaldi C, Campoccia S, Cionini L, Conte PF: Sequential chemoradiation therapy with vinorelbine, ifosfamide and cisplatin in stage IIIB non-small cell lung cancer: A phase II study. Semin Oncol 2000;27(suppl 1):28–32.
36.
Montalar J, Morales S, Maestu I, Camps C, Vadell C, Garcia R, Yuste AL, Torregrosa D, Segura A: Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;34:305–311.
37.
Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzmeier U, Jaworski M, Burillon JP, Aubert D: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients. Ann Oncol 2002;13:1853–1861.
38.
Recchia F, De Filippis S, Rosselli M, Pompili P, Guerriero G, Rea S: Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study. Eur J Cancer 1999;35:1457–1461.
39.
Recchia F, Lombardo M, De Filippis S, Rosselli M, Rea S: Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: A phase II study. Anticancer Res 2002;22:1321–1328.
40.
Baldini E, Ardizzoni A, Prochilo T, Caffarata MA, Boni L, Tibaldi C, Neumaier C, Conte PF, Rosso R: Gemcitabine, ifosfamide and navelbine (GIN): Activity and safety of a non-platinum-based triplet in advanced non-small cell lung cancer. Br J Cancer 2001;85:1452–1455.
41.
Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ: A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced non-small cell lung carcinoma. Cancer 2000;89:774–782.
42.
Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP: A phase I–II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced non-small cell lung cancer. Int J Cancer 2002;98:141–147.
43.
Kunitoh H, Akiyama Y, Kusaba H, Yamamoto N, Sekine I, Ohe Y, Kubota K, Tamura T, Sekine I, Yuichiro O, Kubota K, Tamura T, Shinkai T, Kodama T, Goto K, Niho S, Nishiwaki Y, Saijo N: A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer. Lung Cancer 2001;33:259–265.
44.
Crown J, Fennelly D, Collins C, Jones M, Ennis S, Rowan S, Flynn C, Nutty S, Armstrong J, Moulton B: Mature results of a phase I/II evaluation of docetaxel, ifosfamide, cisplatin supported by lenograstim in patients with advanced non-small cell lung cancer: An Irish Clinical Oncology Research Group (ICORG). 25th European Society for Medical Oncology Congress, Oct 2000, Hamburg. Ann Oncol 2000;11(suppl 4):118.
45.
Zaniboni A, Meriggi F, Rizzi A, Alghisi A, Pascarella A, Bozzola G, Mutti S, Marini G: Paclitaxel, ifosfamide and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: Preliminary results. Semin Oncol 1997;24(suppl 12):12–70.
46.
Palackdharry CS: Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: Preliminary results. Semin Oncol 1996;23(suppl 6):78–83.
47.
Mohedano N, Medina MB, Sanchez P: Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer. 8th World Conference on Lung Cancer, Dublin 1997, p 18).
48.
Barneto IC, De La Hara J, Gosalbez B, Artal A, Anton A, Aranda E: Phase II activity of cisplatin, plus ifosfamide and gemcitabine in non-small cell lung cancer: Preliminary results. 8th World Conference on Lung Cancer, Dublin 1997, p 8.
49.
Vadell C, Carles J, Gallen M: Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial. 8th World Conference on Lung Cancer, Dublin 1997, p 18.
50.
De Las Penas R, Busquier I, Munarriz J: Phase II study of gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer. Ann Oncol 1998;9:88.
51.
Crinò L, Scagliotti G, Marangolo M: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1997;15:297–303.
52.
Boni C, Bisagni G, Savoldi L, Moretti G, Rondini E, Sassi M, Zadro A, De Pas T, Franciosi V, Pazzola A, Vignoli R, Banzi MC, Pajetta V: Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian Oncology Group for Clinical Research (GOIRC). Int J Cancer 2000;87:724–727.
53.
Chen YM, Perng RP, Whang-Peng J, Wu HW, Lin WC, Tsai CM: Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer. Lung Cancer 2000;30:199–202.
54.
Tognoni A, Pensa F, Vaira F, Vigani A, Bancalari L, Fiasella L, Maggiani R, Canessa P, Pronzato P: A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small cell lung cancer. J Chemother 2001;13:202–205.
55.
Marini G, Ferrari VD, Marpicati P, Montini E, Rangoni G, Simoncini E, Bozzola G, Caprioli A, Tassi GF: Gemcitabine in combination with ifosfamide and cisplatin in advanced non-small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol 1999;18:1989a.
56.
Cartei G, Sacco C, Sibau A, Tumolo S, Caffo O, Lucenti A, De Pangher VM, Vigevani E, Iop A, RosaBian A, Bearz A, Gusella M, Segati R, Tabaro G: Gemcitabine, ifosfamide and platin in non-small cell lung cancer: An intention-to-treat phase II ‘EOLO’ study. Proc Am Soc Clin Oncol 1999;18:1923a.
57.
Boni C, Ardizzoni A, Baldini E, Barone C, Bianco AR, Boni L, Recchia F, Santomaggio C: Efficacy comparison of two doublets and two triplets with vinorelbine replacing cisplatin and the addition of ifosfamide to two-drug regimens in the treatment of advanced NSCLC: A phase III factorial, randomized multicenter study (ongoing study).
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.